A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

PLoS Biology

Volumn 14, Issue 1, 2016, Pages

  de Jong, Rob N ^a   Beurskens, Frank J ^a   Verploegen, Sandra ^a   Strumane, Kristin ^a   van Kampen, Muriel D ^a   Voorhorst, Marleen ^a   Horstman, Wendy ^a   Engelberts, Patrick J ^a   Oostindie, Simone C ^a   Wang, Guanbo ^b,c   Heck, Albert J R ^b,c   Schuurman, Janine ^a   Parren, Paul W H I ^a,d,e  

^a GENMAB   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

11 B8; 7 D8; 7 D8 E34 5R; 7 D8 K 332A; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD38 ANTIGEN; CD52 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; OBINUTUZUMAB; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAJI CELL LINE; ANIMAL; CANCER TRANSPLANTATION; EVALUATION STUDY; GENETICS; IMMUNOTHERAPY; METABOLISM; MUTATION; POLYMERIZATION; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; POLYMERIZATION;

EID: 84956718998     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002344     Document Type: Article

References (44)

1. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–3. Epub 2014/03/15. doi: 10.1126/science.1248943 343/6176/1260 [pii]. 24626930.
2. Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW, Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67(2 Pt A):117–30. Epub 2015/02/24. doi: 10.1016/j.molimm.2015.01.028 S0161-5890(15)00038-3 [pii]. 25697848.
3. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005–10. Epub 2006/03/16. doi: 0508123103 [pii] doi: 10.1073/pnas.0508123103 16537476; PubMed Central PMCID: PMC1389705.
4. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR, Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7(8):2517–27. Epub 2008/08/30. 18723496. doi: 10.1158/1535-7163.MCT-08-0201
5. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591–604. Epub 2000/11/30. M009483200 [pii]. 11096108.
6. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O, Structural Difference in the Complement Activation Site of Human IgG1 and IgG3. Scand J Immunol. 2009;70(6):553–64. doi: 10.1111/j.1365-3083.2009.02338.x 19906198
7. Isenman DE, Dorrington KJ, Painter RH, The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol. 1975;114(6):1726–9. Epub 1975/06/01. 1127227.
8. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164(8):4178–84. Epub 2001/02/07. 10754313.
9. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, et al. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166(4):2571–5. Epub 2001/02/13. 11160318.
10. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H, Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol. 2006;177(2):1129–38. Epub 2006/07/05. 16818770.
11. Moore GL, Chen H, Karki S, Lazar GA, Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs. 2010;2(2):181–9. Epub 2010/02/13. doi: 11158 [pii]. 20150767; PubMed Central PMCID: PMC2840237.
12. Collins C, Tsui FW, Shulman MJ, Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol. 2002;32(6):1802–10. Epub 2002/07/13. 12115664.
13. Burton DR, Is IgM-like dislocation a common feature of antibody function? Immunol Today. 1986;7(6):165–7. doi: 10.1016/0167-5699(86)90166-0 25290200
14. Smith RI, Coloma MJ, Morrison SL, Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol. 1995;154(5):2226–36. Epub 1995/03/01. 7868896.
15. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–52. Epub 2002/10/24. 12393541.
16. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793–800. Epub 2004/06/03. 15172969.
17. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62(4):873–82. Epub 1983/10/01. 6349718.
18. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8. Epub 2010/12/29. 21187443. doi: 10.4049/jimmunol.1003032
19. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008;68(13):4998–5003. Epub 2008/07/03. 18593896. doi: 10.1158/0008-5472.CAN-07-6226
20. Saphire EO. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science. 2001;293(5532):1155–9. 11498595
21. DeLano WL, Ultsch MH, de Vos AM, Wells JA, Convergent solutions to binding at a protein-protein interface. Science. 2000;287(5456):1279–83. 10678837
22. Halaby DM, Poupon A, Mornon J, The immunoglobulin fold family: sequence analysis and 3D structure comparisons. Protein Eng. 1999;12(7):563–71. Epub 1999/08/06. 10436082.
23. Heck AJ, Native mass spectrometry: a bridge between interactomics and structural biology. Nat Methods. 2008;5(11):927–33. Epub 2008/11/01. doi: 10.1038/nmeth.1265 nmeth.1265 [pii]. 18974734.
24. Yadav S, Liu J, Shire SJ, Kalonia DS, Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci. 2010;99(3):1152–68. Epub 2009/08/26. doi: 10.1002/jps.21898 19705420.
25. Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW, Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol. 2014;426(8):1799–811. Epub 2014/02/14. doi: 10.1016/j.jmb.2014.01.011 S0022-2836(14)00069-2 [pii]. 24522230.
26. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G, Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol. 2012;7(9):1596–602. Epub 2012/07/04. doi: 10.1021/cb300130k 22747430; PubMed Central PMCID: PMC3448853.
27. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P, Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325(5):979–89. Epub 2003/01/16. doi: S0022283602012500 [pii]. 12527303.
28. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–66. Epub 1994/10/15. 7522629.
29. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–402. Epub 2010/03/03. doi: 10.1182/blood-2009-06-225979 blood-2009-06-225979 [pii]. 20194898; PubMed Central PMCID: PMC2881503.
30. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173(7):4699–707. Epub 2004/09/24. 15383606.
31. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266(5187):1024–7. Epub 1994/11/11. 7973652.
32. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP, Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol. 1992;87(1):105–10. Epub 1992/01/01. 1339322; PubMed Central PMCID: PMC1554244.
33. Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN, A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 2014;65(1):5–10. Epub 2013/07/23. doi: 10.1016/j.ymeth.2013.07.018 S1046-2023(13)00267-3 [pii]. 23872061.
34. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011;187(6):3383–90. Epub 2011/08/13. 21832160. doi: 10.4049/jimmunol.1003926
35. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749–58. Epub 2009/06/19. 19535640. doi: 10.4049/jimmunol.0900632
36. Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, et al. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure. 2011;19(9):1274–82. Epub 2011/09/07. 21893287. doi: 10.1016/j.str.2011.06.016
37. Tahallah N, Pinkse M, Maier CS, Heck AJ, The effect of the source pressure on the abundance of ions of noncovalent protein assemblies in an electrospray ionization orthogonal time-of-flight instrument. Rapid Commun Mass Spectrom. 2001;15(8):596–601. Epub 2001/04/20. 11312509.
38. van den Heuvel RH, van Duijn E, Mazon H, Synowsky SA, Lorenzen K, Versluis C, et al. Improving the performance of a quadrupole time-of-flight instrument for macromolecular mass spectrometry. Anal Chem. 2006;78(21):7473–83. Epub 2006/11/01. 17073415.
39. Wang G, Johnson AJ, Kaltashov IA, Evaluation of electrospray ionization mass spectrometry as a tool for characterization of small soluble protein aggregates. Anal Chem. 2012;84(3):1718–24. Epub 2012/01/14. doi: 10.1021/ac203017x 22240037.
40. Kabat EA, Bethesda MD, Sequences of proteins of immunological interest. NIH publication n° 91–3242. 5th edition ed. USA: National Institutes of Public Health; 1991. p. 662, 80, 89.
41. Holm L, Park J, DaliLite workbench for protein structure comparison. Bioinformatics. 2000;16(6):566–7. Epub 2000/09/12. 10980157.
42. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 2011;16(11):1071–80. Epub 2011/10/26. doi: 10.1111/j.1365-2443.2011.01552.x 22023369; PubMed Central PMCID: PMC3258418.
43. Siberil S, Menez R, Jorieux S, de Romeuf C, Bourel D, Fridman WH, et al. Effect of zinc on human IgG1 and its FcgammaR interactions. Immunol Lett. 2012;143(1):60–9. Epub 2012/05/04. 22553781.
44. Bowden TA, Baruah K, Coles CH, Harvey DJ, Yu X, Song BD, et al. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc. 2012;134(42):17554–63. Epub 2012/10/03. doi: 10.1021/ja306068g 23025485; PubMed Central PMCID: PMC3593610.